Search Results

1 - 10 of 14 items :

  • "nephrectomy" x
  • Internal Medicine x
Clear All
Neutrophil-Gelatinase Associated Lipocalin (N-GAL) to Assess Perioperative Acute Kidney Injury in Hand-Assisted Laparoscopic Donor Nephrectomy: A Pilot Study

References 1. Jacobs S, Cho E, Foster C, et al. Laparoscopic donor nephrectomy: The University of Maryland 6-year experience. The Journal of Urology 2004; 171(1): 47-51. 2. Flowers JL, Jacobs S, Cho E, et al. Comparison of open and laparoscopic live donor nephrectomy. Ann Surg 1997; 226 (4): 483-490. 3. London ET, Ho HS, Neuhaus AMC, et al. Effect of intravascular volume expansion on renal function during prolonged CO2 pneumoperitoneum. Ann Surg 2000; 231: 195-201. 4. Mishra J, Dent C, Tarabishi

Open access
Rare Case of Clear Cell Renal Cell Carcinoma Metastasizing to Contralateral Kidney and Ipsilateral Parotid more than five Years following Nephrectomy

carcinoma in the head and neck: An evaluation of 22 cases in 671 patients. Int Braz J Urol, 2017;43:202-208. 9. Hussain F, Yedavalli N, Loeffler D, Kajdacsy-Balla A. Solitary parotid metastasis 8 years after a nephrectomy for renal cell carcinoma. J Community Hosp Intern Med Perspect, 2016; 6:31950. 10. Majewska H, Skálová A, Radecka K, Stodulski D, Hyrcza M, Stankiewicz C, et al. Renal clear cell carcinoma metastasis to salivary glands - a series of 9 cases: clinicopathological study. Pol J Pathol, 2016;1:39-45. 11. Balaban M, Vudali Dogruyol S, Idilman

Open access
Isolated Metachronic Metastatic Clear Cell Renal Cell Carcinoma in the Thyroid gland 7 Years After Nephrectomy

Abstract

Thyroid gland is a rare site for distant metastases. The aim of this study is to present a rare case of an isolated metastatic clear cell renal cell cancer (ccRCC) in the thyroid gland seven years after left-sided nephrectomy.

A neck cancer discovered by clinical examination, diagnosed by ultrasound-guided USG fine-needle biopsy was removed by surgery. Palliative thyroidectomy with consecutive neck radiotherapy was finished without any complications, except a temporary, asymptomatic hypocalcaemia. After six month remission, the patient’s general condition deteriorated, multiorgan RCC dissection appeared leading to the patient’s death

Open access
Kidney cancer

Kidney cancer

Background. The purpose of this paper is to present the epidemiology, diagnostic workup and treatment of renal cell carcinoma (RCC) with an emphasis on the Slovenian epidemiological data. RCC represents 2% of all cancers and is the third most common genitourinary tract tumour. It most frequently occurs among people of ages, between 50 and 60 years. Male patients are more prone to it than female. A number of environmental, occupational and genetic factors have been found to be associated with the development of RCC. Patients often have nonspecific symptoms and this is the reason why for half of them the disease is already metastatic when diagnosed. The most common sites of metastases are lungs (75%), followed by soft tissues (36%), bones (20%), liver (18%), skin (8%) and central nerve system (8%). In the evaluation of RCC multiple diagnostic procedures are needed with obligatory image diagnostics.

Conclusions. Radical nephrectomy is still the mainstream treatment of localized disease. Nephron sparing techniques have been used in cases, where radical operation would result in an anephric patient. Efficient adjuvant therapy has not been discovered yet. Until recently interpherone and interleukin were the only known effective treatments for metastatic disease, but now new and more efficient biologic agents are being discovered. The most important prognostic factor for survival is stage at the beginning of treatment. The 5-year survival rate is 95% for patients with stage I disease, 88% for stage II, 59% for stage III and 20% for stage IV.

Open access
Developing an algorithm for the management of Renal Cell Carcinoma: focus on metastatic disease

patients with localised clear-cell RCC at high risk for tumour recurrence after nephrectomy (pT > 3 and/ or pN+) (21) . Adverse events were significantly higher with sunitinib treatment. The recent results from PROTECT trial, unfortunately, did not offer conclusive evidence in favour or against adjuvant treatment. Adjuvant administration of pazopanib did not meet its primary endpoint of prolonging DFS [hazard ratio: 0.862; 95% confidence interval, 0.699, 1.063; p = 0.165] in the decreased dosage of 600 mg daily, which was needed in order to control toxicity

Open access
25th Hellenic conference of Clinical Oncology

with renal cell carcinoma with multiple lung metastases. He underwent left nephrectomy in November 2016 and he was addressed to the oncology department for further treatment. He started treatment with sunitinib50 mg per day, 4 weeks/6, with initial creatinine clearance of 40 ml/min. Results : After 2 months of treatment creatinine level moved to 2.84 mg/dl and 2 months later to 3.43mg/dl. The patient developed proteinuria over 3 gr/24h. Sunitinib was discontinued and imaging reevaluation was performed, which revealed a complete response. Two months later

Open access
Skeletal Muscle Metastases and Inferior Vena Cava Involvement in a Patient with Clear Cell Renal Cell Carcinoma and Sarcomatoid Differentiation

REFERENCES 1. Togral G, Arıkan M, Gungor S. Rare skeletal muscle metastasis after radical nephrectomy for renal cell carcinoma: evaluation of two cases. J Surg Case Rep . 2014;2014(10):rju101. 2. Sountoulides P, Metaxa L, Cindolo L. Atypical presentations and rare metastatic sites of renal cell carcinoma: a review of case reports. J Med Case Reports . 2011;5:429. 3. Shuch B1, Bratslavsky G, Linehan WM, Srinivasan R. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist . 2012

Open access
Is Chronic Kidney Disease Reversible?

References 1.Olson JL, Heptinstall RH (1988) Nonimmunologic mechanisms of glomerular injury. Lab Invest 59:564578 2.Morrison AB, Howard RM (1966) The functional capacity of hypertrophied nephrons: effect of partial nephrectomy on the clearance of inulin and PAH in the rat. J Exp Med 123:829844 5. 3.Shimamura T, Morrison AB (1975). A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol 79:95106 4.Brenner BM, Meyer TW, Hostetter TH (1982) Dietary protein intake and the progressive nature of kidney

Open access
Efficacy of long-term low-dose sulodexide in diabetic and non-diabetic nephropathies

: 1083-1091. 19. HEERSPINK HL, GREENE T, LEWIS JB, et al. Collaborative Study Group. Effects of Sulodexide in patients with type 2 diabetes and persistent albuminuria . Nephrol Dial Transplant 2008; 23 (6):1946–1954. 20. LI P, MA LL, XIE RJ, et al. Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure . Acta Pharmacologica Sinica 2012; 33 : 644–651.

Open access
The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma

cell carcinoma: perspectives of primary prevention. World J Urol 2010; 28: 247-52. 5. Klatte T, Pantuck AJ, Kleid MD, Belldegrun AS. Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol 2007; 9: 47-56. 6. Bukowski RM. Prognostic factors for survival in metastatic renal cell carcinoma: update 2008. Cancer 2009; 115: 2273-81. 7. Cruz A, Ramírez LM, Sánchez E, Ruiz M, Moreno I, López J, et al. Gastric metastasis from renal cancer six years after nephrectomy. Rev Esp Enferm

Open access